Financial results for the period ended September 30, 2026
As filed · Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
What happened
FactFinancial results for the period ended September 30, 2026. The Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30. Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.l, Hyderabad.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
WithdrawnOur medium-term objective is to qualify approximately two new products each year, combining opportunities with the existing anchor customer and new customer across Europe and Japan.
The photochromic portfolio remained balanced, supported by our established chemistry platforms and customer relationships.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Our vision of a US$1 billion business by 2030 remains there. We are committed to reach there. (management committed by FY30)
- our vision for US$1 billion by 2030. (management committed by FY30)
Evidence
- Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%